Bioness Inc. Announces A Notification For Allowance From The U.S. Patent And Trademark Office For Stimrouter Neuromodulation System

VALENCIA, Calif.--(BUSINESS WIRE)--Bioness, Inc. announces a Notification for Allowance from the U.S. Patent and Trademark Office (USPTO) for a patent claiming use of high frequency stimulation using the StimRouter, an implantable neuromodulation device that has FDA clearance to treat chronic, intractable pain of peripheral nerve origin as an adjunct to other modes of therapy. StimRouter is the only implantable neuromodulation device indicated and marketed to treat chronic pain of peripheral nerve origin.

“There is a healthy debate with regards to the efficacy of low frequency vs. high frequency in specific neuromodulation applications. StimRouter was designed as a platform technology and this patent allowance from the USPTO is a testament to Bioness’ efforts to expand the opportunity of this unique neuromodulation system.”

Bioness Chief Technology Officer Keith McBride commented, “There is a healthy debate with regards to the efficacy of low frequency vs. high frequency in specific neuromodulation applications. StimRouter was designed as a platform technology and this patent allowance from the USPTO is a testament to Bioness’ efforts to expand the opportunity of this unique neuromodulation system.”

The USPTO expanded the patent scope of the StimRouter Technology Platform for use by both activating the nerves using low frequency stimulation and blocking (inhibiting) the activation for treatment of urinary retention, incontinence, pain, an autonomic disorder, spasticity, tremor, muscle weakness, Parkinson’s disease, and dystonia. The expanded scope allows StimRouter to supply electrical current in cyclical waveform at a frequency in the range of 100 Hz to 30 kHz for blocking targeted tissues.

About StimRouter™ Neuromodulation System

StimRouter is cleared by the FDA to treat chronic pain of peripheral nerve origin. StimRouter is a minimally invasive neuromodulation medical device consisting of an implanted lead, external pulse transmitter (EPT) and conductive electrode, controlled by a small, hand-held wireless control unit. Electrical signals are transmitted transdermally from the EPT through the electrode, down the lead to the target nerve. StimRouter is programmed at the direction of the physician to meet patient requirements.

About Bioness Inc.

Bioness is the leading provider of innovative technologies helping people regain mobility and independence. Bioness solutions include external and implantable functional electrical stimulation (FES) systems, robotic systems and software-based therapy programs providing functional and therapeutic benefits for individuals affected by pain, central nervous system disorders and orthopedic injuries. Individual results vary. Consult with a qualified physician to determine if this product is right for you. Contraindications, adverse reactions and precautions are available online at www.bioness.com

StimRouter™ and Bioness^® are trademarks of Bioness Inc. | www.bioness.com | Rx Only

Additional information about StimRouter can be found at www.stimrouter.com.